Characteristics of Short-Term Survivors With ALK or ROS1-Altered Metastatic NSCLC
Lists
Only you see this
Abstract
Among patients with <i>ALK</i>+ but not <i>ROS1</i>+ mNSCLC, the presence of liver metastases at baseline and on-treatment was associated with worse survival. In the ALK+ population, the cumulative incidence of brain but not liver metastases is improving, highlighting a need for therapies effective at the treatment and prevention of liver metastases.
BibTeX
@inproceedings{liu2025characteristics,
author = {Kai Liu and Alan G. Watts and Connor B. Grady and Geoffrey Liu and Devalben Patel and Karmugi Balaratnam and Stephen V. Liu and Gabriela Bravo and Yunan Nie and Jorge J. Nieva and Amanda Herrmann and Kristen A. Marrone and Vincent K. Lam and Fangdi Sun and Jonathan E. Dowell and William Schwartzman and Vamsidhar Velcheti and Olivia Fankuchen and Tasfiq Ullah and L. Villaruz and Matthew K. Nguyen and Jared Weiss and Shetal Patel and Kelsey Miller and Wade T. Iams and Krishna Chandrasekhara and William Tompkins and Tejas Patil and Dara L. Aisner and D. Ross Camidge and Wei‐Ting Hwang and Lova Sun and Melina E. Marmarelis},
title = {{Characteristics of Short-Term Survivors With ALK or ROS1-Altered Metastatic NSCLC}},
booktitle = {JTO},
year = {2025},
doi = {10.1016/j.jtocrr.2025.100876},
}Loading related content...